Opinion|Videos|March 12, 2025
The Shifting Paradigms With Perioperative Treatment Strategies in Early-Stage NSCLC
Panelists discuss how recent data from KEYNOTE-671, AEGEAN, and CheckMate 77T reinforce neoadjuvant therapy’s efficacy in early-stage non–small cell lung cancer (NSCLC), showing consistent survival benefits. In contrast, adjuvant data remain conflicting, limiting its role. Neoadjuvant therapy should be prioritized, with adjuvant therapy reserved for select high-risk patients.
Advertisement
Video content above is prompted by the following:
- What are your perspectives on the latest efficacy, safety data, and recent approvals in early-stage NSCLC treatment, and how have these influenced your clinical practice?
- KEYNOTE-671: Wakelee H, et al. NEJM. 2023;389:491-503.
- AEGEAN: Heymach JV, et al. WCLC 2024. Abs OA13.03. (Approval August 2024)
- CheckMate 77T: Spicer J, et al. ESMO 2024. LBA50(Approval October 2024)
- Briefly comment on the conflicting data in the adjuvant setting and contrast that with the consistency demonstrated in the neoadjuvant setting, and discuss how you translate this into your clinical practice.
- Should neoadjuvant therapy be recommended for all patients who do not proceed directly to surgery?
- In which patients should adjuvant therapy be added, and what is the remaining role for adjuvant therapy alone?
Advertisement
Related to this article
Risvutatug rezetecan met the primary OS end point of the phase 3 ARTEMIS-008 trial in Chinese patients with relapsed small-cell lung cancer.
Phase 3 ELEVATE data show that adjuvant ensartinib significantly improved disease-free survival vs placebo in resected ALK-positive NSCLC.
A study from the Northwestern Medicine Canning Thoracic Institute indicates that lung transplant can extend survival in select advanced lung cancer cases.
Divarasib demonstrated superior PFS and OS versus sotorasib or adagrasib in the phase III Krascendo 1 trial in previously treated KRAS G12C–mutant NSCLC.
Faculty members gathered at an OncLive Scientific Interchange and Workshop to discuss individualizing care in EGFR-mutated NSCLC.
Panelists discuss how nodal burden, NGS turnaround time, and regional resource heterogeneity shape treatment sequencing in EGFR-mutated NSCLC in Latin America.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Pembrolizumab Plus Enfortumab Vedotin in MIBC
2
Interpreting Efficacy Data and Assessing Risk-Benefit in a Curative-Intent Population
3
FDA Flashback: Breast Cancer Decisions and News From June 2026
4
FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma
5